543 Cis-binding/blockade of CD47 by CD47xPD1 BsAb HX009 enhanced PD1 blockade induced T-cell activation

543 Cis-binding/blockade of CD47 by CD47xPD1 BsAb HX009 enhanced PD1 blockade induced T-cell activation

Bibliographic Details
Main Authors:	Faming Zhang, Henry Li, Hang Ke, Cen Chen
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2023-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

HX009, a novel BsAb dual targeting PD1 x CD47, demonstrates potent anti-lymphoma activity in preclinical models
by: Hang Ke, et al.
Published: (2023-04-01)

Overcoming immunotherapeutic resistance in PDAC: SIRPα-CD47 blockade
by: Abdullahi Alausa, et al.
Published: (2022-07-01)

CD47 blockade enhances phagocytosis of cardiac cell debris by neutrophils
by: Elias Haj-Yehia, et al.
Published: (2023-10-01)

A Novel Blockade CD47 Antibody With Therapeutic Potential for Cancer
by: Fangzhen Lin, et al.
Published: (2021-01-01)

Synergistic effect of CD47 blockade in combination with cordycepin treatment against cancer
by: Chen Feng, et al.
Published: (2023-04-01)

Durable antitumor responses to CD47 blockade require adaptive immune stimulation
by: Sockolosky, Jonathan T., et al.
Published: (2016)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
by: David Escors, et al.
Published: (2022-10-01)

CD47 blockade ameliorates autoimmune vasculitis via efferocytosis of neutrophil extracellular traps
by: Satoka Shiratori-Aso, et al.
Published: (2023-08-01)

Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma
by: Xingxing Gao, et al.
Published: (2022-09-01)

CD47: The Next Frontier in Immune Checkpoint Blockade for Non-Small Cell Lung Cancer
by: Asa P. Y. Lau, et al.
Published: (2023-10-01)

Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
by: Tobias Zeller, et al.
Published: (2022-10-01)

YB-1-based oncolytic virotherapy in combination with CD47 blockade enhances phagocytosis of pediatric sarcoma cells
by: Anna Josefine von Ofen, et al.
Published: (2024-01-01)

Gradient material Pd-PdHx
by: M. V. Goltsova, et al.
Published: (2018-10-01)

Functional systemic CD4 immunity is required for clinical responses to PD‐L1/PD‐1 blockade therapy
by: Miren Zuazo, et al.
Published: (2019-07-01)

Combination CD200R/PD-1 blockade in a humanised mouse model
by: Fellermeyer, M, et al.
Published: (2023)

CD47 antibody blockade suppresses microglia-dependent phagocytosis and monocyte transition to macrophages, impairing recovery in EAE
by: Huan Wang, et al.
Published: (2021-11-01)

Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
by: Yun Yang, et al.
Published: (2023-12-01)

Tolerating CD47
by: Jeffrey S. Isenberg, et al.
Published: (2024-02-01)

471 CD47 blockade as a targeted immune oncology agent in head and neck squamous cell carcinoma model
by: Robert Saddawi-Konefka, et al.
Published: (2023-11-01)

Lung‐specific exosomes for co‐delivery of CD47 blockade and cisplatin for the treatment of non–small cell lung cancer
by: Zhilei Cui, et al.
Published: (2022-10-01)

Targeting CD96 overcomes PD-1 blockade resistance by enhancing CD8+ TIL function in cervical cancer
by: Meng Zhang, et al.
Published: (2022-03-01)

Blockade of PD-1 and LAG-3 expression on CD8+ T cells promotes the tumoricidal effects of CD8+ T cells
by: Jiajia Ma, et al.
Published: (2023-09-01)

Discovery of a novel small molecule as CD47/SIRPα and PD-1/PD-L1 dual inhibitor for cancer immunotherapy
by: Shengzhe Jin, et al.
Published: (2024-03-01)

PD-1 blockade potentiates neoadjuvant chemotherapy in NSCLC via increasing CD127+ and KLRG1+ CD8 T cells
by: Zhenzhen Hui, et al.
Published: (2023-05-01)

Enhanced potency of immunotherapy against B‐cell precursor acute lymphoblastic leukemia by combination of an Fc‐engineered CD19 antibody and CD47 blockade
by: Denis M. Schewe, et al.
Published: (2024-02-01)

TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis
by: Friedrich Haag, et al.
Published: (2022-12-01)

Liposome-Based Co-Immunotherapy with TLR Agonist and CD47-SIRPα Checkpoint Blockade for Efficient Treatment of Colon Cancer
by: Rui Chang, et al.
Published: (2023-03-01)

CD69 and SBK1 as potential predictors of responses to PD-1/PD-L1 blockade cancer immunotherapy in lung cancer and melanoma
by: Zhang-Wei Hu, et al.
Published: (2022-08-01)

Biomarkers of response to PD-1 pathway blockade
by: Li, H, et al.
Published: (2022)

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T Cells
by: Regev, Aviv
Published: (2020)

Circulating Exhausted PD-1<sup>+</sup>CD39<sup>+</sup> Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
by: Carlos Martinez-Gomez, et al.
Published: (2022-07-01)

1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
by: Chao Wang, et al.
Published: (2023-11-01)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
by: Hiroo Katsuya, et al.
Published: (2023-11-01)

Towards the Application of a Label-Free Approach for Anti-CD47/PD-L1 Bispecific Antibody Discovery
by: Artem S. Grevtsev, et al.
Published: (2023-12-01)

The Generation of Dual-Targeting Fusion Protein PD-L1/CD47 for the Inhibition of Triple-Negative Breast Cancer
by: Yanlin Bian, et al.
Published: (2022-07-01)

STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma
by: Peng Zhang, et al.
Published: (2023-03-01)

Impact of CD4 T cells on intratumoral CD8 T-cell exhaustion and responsiveness to PD-1 blockade therapy in mouse brain tumors
by: Andrew Coxon, et al.
Published: (2022-12-01)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
by: Laura Jimbu, et al.
Published: (2021-03-01)

PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
by: Sandra Bufe, et al.
Published: (2022-10-01)

CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models
by: Jian Ye, et al.
Published: (2023-05-01)